Therapeutic Innovations in Parkinson’s and Alzheimer’s Disease: Molecular Mechanisms and Emerging Strategies

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · Published 2026-04-13 · DOI 10.2174/0118715273445849260403045802

Authors being retrieved — see the publisher record. https://doi.org/10.2174/0118715273445849260403045802

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• MicroRNAs as Molecular Modulators in Stroke: Pathogenic Mechanisms and Therapeutic Avenues · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Early Anti-CD20 and CNS Penetrant BTK Inhibition to Enhance OPC-Driven Remyelination in Multiple Sclerosis · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Neuroinflammatory and Synaptic Roles of Glial Cells in Autism SpectrumDisorder · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Redefining Parkinson’s Care: The Promise of Nanotechnology and Artificial Intelligence · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• The Effect of a Novel Antibody-based Drug, Prospekta, on Brain Electrical Activity in Mice · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Synthetic Imidazole Derivatives as Multitarget Agents in Depression:Insights into Mechanism and Therapeutic Promise · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Brigatinib in ALK-fused, Low-grade Pediatric Angiocentric Glioma withMultiple Extracranial Metastases: A Case Report · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Re-Profiling and Re-purposing of FDA-Approved AntiViral AgentsAgainst Neurological Targets of Memory and Cognition: MolecularDocking and Simulation Approach · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Mitochondrial Dysfunction in Parkinson's Disease: Diagnostic andTherapeutic Advances · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Fluorescent Carbon Dots for Neurodegenerative Disorders · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal